ArchiMed has acquired a majority controlling stake in Deallus Consulting. No financial terms were disclosed. Based in London, Deallus is a life sciences industry consultant.
November 9, 2015 – ArchiMed, Europe’s fist independent private equity healthcare specialist, acquires majority control of Deallus Consulting today.
Deallus is a global life sciences industry consultant working with 25 of the world’s top 30 pharmaceutical, biotechnology and vaccine companies, and a wide range of small and medium-size firms. Employing extensive proprietary data and competitive intelligence, Deallus provides a full range of consulting services, advising on everything from product introduction to processes for sustaining corporate innovation.
Since Deallus’ founding in 2004, annual revenue growth has averaged some 20 percent. Turnover in the company’s most recent fiscal year was £15 million. Deallus’ 80 consultants work from headquarters in London, and offices in New York, Los Angeles, Princeton, Tokyo and Singapore.
“Deallus does exactly what a specialist consultant should do, it inspires clients to develop best-in-class strategies through exceptionally deep market understanding and insight,” says Robin Filmer-Wilson, a managing partner of ArchiMed. “We intend to accelerate the growth of Deallus by providing access to new accounts, aiding recruitment and helping to set up additional offices globally.” ArchiMed is also reviewing a number of possible bolt-on acquisitions for Deallus.
No debt was used in the Deallus transaction, which was the result of a proprietary process. Senior managers of Deallus have reinvested all proceeds from the deal into the group, demonstrating their faith in ArchiMed’s plans and their economic alignment with ArchiMed.
“We are excited to work in partnership with ArchiMed and leverage their networks in both the consulting and healthcare industries to take Deallus into the next phase of its growth,” says Claudio D’Ambrosio, the consultancy’s chief executive.
About ArchiMed – Founded by Managing Partners Denis Ribon, Vincent Guillaumot and Robin Filmer-Wilson, along with several colleagues also from the 3i Healthcare team, ArchiMed is the first independent private equity team dedicated to the healthcare sector in Europe. The firm’s inaugural Med 1 fund surpassed its €120 million target, closing on its hard cap of €150 million in June 2015. The team also includes Operating Partner Loïc Kubitza, previously a Leader at PWC’s Healthcare and Life Sciences Practice, and Operating Partner Christoph Böhmer, previously Managing Director of €1 billion-in-revenues cardiovascular leader Biotronik. In the last fifteen years, the ArchiMed team has invested more than €1 billion in 20-plus companies, achieving a total return of over 2.6 times invested capital.